Summary
Objective
Heartburn, regurgitation, pulmonary aspiration, and remnant esophagitis represent common sequelae of esophagectomy and gastric conduit reconstruction. Proton pump inhibitors are the mainstay of treatment. The aim of the study was to focus on the efficacy of combination therapy with mucosal surface protection.
Materials and methods
Patients undergoing esophagectomy were followed up to 1 year. Patients in group A received 60 mg/day lansoprazole and those in group B received combination therapy. During follow-up, the dosage of lansoprazole was reduced to 30 mg/day in asymptomatic patients with or without grade A–B esophagitis. The Gastro-Esophageal Reflux Disease – Health-Related Quality of Life (GERD-HRQL) and the Short-Form 36 (SF-36) were used to assess postoperative quality of life, and the foregut symptom questionnaire to assess the prevalence of regurgitation, respiratory symptoms, and sleep disorders.
Results
Between August 2017 and August 2018, 56 patients were enrolled in the study. Over follow-up, the incidence of refractory symptoms and/or esophagitis grade C–D was 35.7% in group A and 21.4% in group B (p = 0.024). At 1 year, 18 (64.2%) patients in group A and 22 (78.5%) in group B remained symptom free and without severe esophagitis under treatment with 30 mg of lansoprazole (p = 0.076). The GERD-HRQL score was similar at 3 and 6 months (p = 0.790 and p = 0.812, respectively); at 12 months, patients in group B had a lower score although the difference was not significant (p = 0.216). There were no statistically significant differences in terms of SF-36 scores at 1‑year follow-up. Concerning the foregut symptom questionnaire, group B experienced less respiratory symptoms (p = 0.045) and sleep disorders (p = 0.039).
Conclusion
At 1‑year after esophagectomy, combination therapy with 30 mg lansoprazole and Esoxx® appears to be an effective antireflux strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, et al. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg. 2013;17:1193–201.
Bonavina L, Anselmino M, Ruol A, Bardini R, Borsato N, Peracchia A. Functional evaluation of the intrathoracic stomach as an oesophageal substitute. Br J Surg. 1992;72:529–32.
Aly A, Jamieson GG. Reflux after oesophagectomy. Br J Surg. 2004;91:137–41.
Park SY, Lee HS, Jang HJ, Lee JY, Joo J, Zo JI. The role of one-year endoscopic follow-up for the esophageal remnant and gastric conduit after esophagectomy with gastric reconstruction for esophageal squamous cell carcinoma. Yonsei Med J. 2013;54:381–8.
Yamamoto S, Makuuchi H, Shimada H, Chino O, Nishi T, Kise Y, et al. Clinical analysis of reflux esophagitis following esophagectomy with gastric tube reconstruction. J Gastroenterol. 2007;42:342–5.
Okuyama M, Motoyama S, Maruyama K, Sasaki K, Sato Y, Ogawa J. Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy. World J Surg. 2008;32:246–54.
Di Simone MP, Baldi F, Vasina V, Scorrano F, Bacci ML, Ferrieri A, et al. Barrier effect of esoxx(®) on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterol. 2012;5:103–7.
Savarino V, Pace F, Scarpignato C, Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease—efficacy of esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45:631–42.
Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007;20:130–4.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
Dresner SM, Griffin SM, Wayman J, Bennet MK, Hayes N, Raimes SA. Human model of duodenogastro-oesophageal refux in the development of Barrett’s metaplasia. Br J Surg. 2003;90:1120–8.
van der Schaaf M, Johar A, Lagergren P, Rouvelas I, Gossage J, Mason R, et al. Surgical prevention of reflux after esophagectomy. Ann Surg Oncol. 2013;20:3655–61.
Johansson J, Oberg S, Wenner J, Zilling T, Johnsson F, von Holstein CS, et al. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial. Ann Surg. 2009;250:667–73.
Greene CL, DeMeester SR, Worrell SG, Oh DS, Hagen JA, DeMeester TR. Alimentary satisfaction, gastrointestinal symptoms, and quality of life 10 or more years after esophagectomy with gastric pull-up. J Thorac Cardiovasc Surg. 2014;147:909–14.
Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123:114–21.
Funding
This work is supported by AIRES, Associazione Italiana Ricerca ESofago
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S. Siboni, M. Sozzi, M. Capuzzo, A. Buogo, C.G. Riva, D. Ferrari, and L. Bonavina declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Siboni, S., Sozzi, M., Capuzzo, M. et al. Combined pharmacologic antireflux therapy after esophagectomy: effect on symptoms and endoscopic findings at 1-year follow-up. Eur Surg 52, 118–122 (2020). https://doi.org/10.1007/s10353-020-00635-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10353-020-00635-2